Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
OxyContin pills. Photo: Liz O. Baylen/Los Angeles Times via Getty Images
Purdue Pharma, the maker of OxyContin, was willing to pay handsomely to avoid a high-profile, televised trial over the company's role in the opioid crisis.
The big question: How much more is Purdue willing to pay to settle the 1,600 other lawsuits that have been consolidated before a federal judge in Ohio?
- "It’s got to set off a feeding frenzy," University of Georgia law professor Elizabeth Burch said. "There’s blood in the water now."
Driving the news: Purdue reached a $270 million settlement yesterday with Oklahoma, where the first major trial over the opioid epidemic is set to begin in May.
Details, via the Wall Street Journal:
- Purdue will pay Oklahoma just shy of $200 million, most of it to fund a new addiction treatment center. Members of the Sackler family, which founded and controlled Purdue during its OxyContin heyday, will contribute another $75 million.
What we're watching: Purdue has said it's considering declaring bankruptcy, which would likely limit plaintiffs' ability to collect damages they might win at trial.
- That possibility "exerted powerful leverage at the bargaining table in Oklahoma," The New York Times reports, and could jump-start settlement talks in the larger, consolidated case as well.
- Purdue's settlement doesn't affect the other companies Oklahoma is pursuing, including Johnson & Johnson.
Go deeper: Huge national opioids lawsuit moves forward